Abstract
To investigate the relationship between the risk factors associated with intravenous immunoglobulin (IVIG) non-response and the incidence of coronary artery lesions (CAL) in patients with Kawasaki disease (KD). A retrospective study was performed on clinical records of 1953 KD patients who were admitted to hospitals in Shanghai, China, between 1998 and 2007. Related clinical and laboratory findings were studied using univariate and multivariate statistical analyses. Of the 1953 KD patients, 133 (6.8 %) were unresponsive to IVIG therapy, and 356 (18.6 %) developed CAL. The incidence of CAL in the non-responsive IVIG group was significantly different from that in the responsive IVIG group (31.3 vs. 17.6 %). The incidence of IVIG non-response was significantly lower in the patients who received sufficient doses of IVIG than in the patients who received insufficient doses (5.2 vs. 18.1 %). A logistic regression analysis of 1295 patients who received sufficient IVIG doses indicated that cervical lymph node enlargement, CAL, erythrocyte sedimentation rate (ESR) ≥75 mm/h, and platelet count (PLT) ≥530 × 109/L were independent risk factors of IVIG non-response. IVIG non-responders are prone to develop CAL. Initiation of therapy with sufficient IVIG doses at the early stage of the disease is crucial for preventing IVIG non-response. Lymph node enlargement, ESR ≥75 mm/h, and PLT count ≥530 × 109/L are independent risk factors for predicting non-response to sufficient IVIG doses. For patients with the tendency of being unresponsive to IVIG therapy, treatment using sufficient IVIG doses combined with hormones or immunosuppressive agents should be considered to reduce the incidence of IVIG non-response and CAL.
Similar content being viewed by others
References
Du Z, Zhan Y, Zhao D, Du J, Lu S, Yi J, He A, Zhou Z, Ding G, Ling Y, Liu C (2006) Treatment of intravenous immunoglobulin non-response patients and analysis of risk factors. Chin J Pract Pediatr 21(10):738–741
Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C (2003) Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol 24(2):145–148
Fukunishi M, Kikkawa M, Hamana K, Onodera T, Matsuzaki K, Matsumoto Y, Hara J (2000) Prediction of non-responsiveness to intravenous high-dose 1-globulin therapy in patients with Kawasaki disease at onset. J Pediatr 137:172–176
Guggino G, Cimaz R, Accomando S, Pagnini I, Simonini G, Di Liberto D, De Martino M, Dieli F, Sireci G (2012) Increased percentages of tumor necrosis factor-alpha+/interferon-gamma+ T [corrected] lymphocytes and calprotectin+/tumor necrosis factor-alpha+monocytes in patients with acute Kawasaki disease. Int J Immunopathol Pharmacol 1:99–105
Huang G, Jing X, Huang M, Chen S, Huang M, Qiu D, Guo Z, Jiang J, Zhou X, Yu Q, Gui Y, Ning S, Zhang T, Du Z, Yanagawa H, Kawasakil T (2006) Epidemiological investigation of Kawasaki disease patients admitted to the hospitals in Shanghai area from 1998 to 2002. Chin J Evid Based Pediatr 1(1):8–13
Japanese Circulation Society Joint Research Group (2005) Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease. Pediatr Int 47:711–732
Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA, Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association, American Academy of Pediatrics (2004) Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 110(17):2747–2771
Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, Kogaki S, Hara J (2007) Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 166(2):131–137
Wallace CA, French JW, Kahn SJ, Sherry DD (2000) Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 105(6):78–81
Wallace CA, French JW, Kahn SJ, Sherry DD (2000) Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 105(6):E78
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Wei, M., Huang, M., Chen, S. et al. A Multicenter Study of Intravenous Immunoglobulin Non-response in Kawasaki Disease. Pediatr Cardiol 36, 1166–1172 (2015). https://doi.org/10.1007/s00246-015-1138-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00246-015-1138-0